PDCD1 and melanoma: The current 5‐year survival rate of patients with advanced melanoma receiving therapies such as programmed cell death protein 1 (PD‐1)/cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhibitors and v‐Raf murine sarcoma viral oncogene homologue B (BRAF)/mitogen‐activated protein kinase kinase (MEK) inhibitors ranges from ~34% to 52%.1